BERKELEY HEIGHTS, NJ October 3, 2002
- Genta Incorporated (Nasdaq: GNTA) announces that several upcoming
presentations will highlight the central importance of the protein
targeted by Genasense
TM
, Genta's lead anticancer compound. The presentations will take
place at the scientific conference, "Lymphoma & Myeloma 2002".
The meeting will be held at the Crowne Plaza Hotel in New York from
October 3-5, 2002. A complete agenda of the meeting can be accessed
at:
http://www.imedex.com/announcements/l&m02.htm#Reg
Several relevant presentations include: Title: "New Molecules in
the Treatment of Myeloma: SAHA, Bcl-2 antisense and Gallium" When:
Friday, October 4, 11:50 AM Presenter: Dr. Rubin Niesvizky, Center
for Lymphoma and Myeloma, Weill Medical College of Cornell
University, The New York Presbyterian Hospitals Title: "The Role of
Bcl-2 in Lymphoma" When: Friday, October 4, 3:10 PM Presenter:
Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver,
Canada Title: "Anti-sense Approaches for Lymphoma" When: Friday,
October 4, 5:30 PM Presenter: Cy A. Stein, Ph.D, Columbia
University, College of Physicians & Surgeons About Genasense
TM
Genasense
TM
works by inhibiting the production of Bcl-2, a protein made
by cancer cells that is thought to block chemotherapy-induced cell
death. By reducing the amount of Bcl-2 in cancer cells, Genasense
TM
may enhance the effectiveness of current anticancer
treatments. About Genta Genta Incorporated is a biopharmaceutical
company with a diversified product portfolio that is focused on
anticancer therapy. The Company's research platform is anchored by
oligonucleotide chemistry, particularly applications of antisense
and decoy aptamer technology. Genasense
TM
, the Company"s lead compound, is being developed in collaboration
with Aventis and is currently undergoing late-stage, Phase 3
clinical testing in several clinical indications. Genta's pipeline
also comprises a portfolio of small molecules, including
gallium-containing compounds and Androgenics compounds for prostate
cancer. For more information about Genta, please visit our website
at:
http://www.genta.com/
.
